About Virchow

	Introduction Our Virchow Group embarked operations in 1981 in the field of API (Active Pharmaceutical Ingredient). We are today the World’s largest producers of API Sulfamethoxazole and Ranitidine. In fact more than 90% of API Sulfamethoxazole and over 60% of Ranitidine worldwide requirements are produced by our group. We pioneered the development of novel and innovative products based on advances in Recombinant DNA and Molecular biology. Our group companies are leading manufacturers of Cephalosporin and various other APIs & Biopharmaceutical giants worldwide.Our state-of-the-art production facilities have efficient modern equipment and with an USFDA, EU GMP, WHO GMP approvals. Our unrelenting commitment to Biotechnology is prompting us to create innovations, leading on to multiple applications as well. We are the first Indian Company to manufacture Biotech products viz; rhPTH (Teriparatide), Interferon, Pegylated Interferon, Platelet derived Growth Factor (PDGF).

	Inspiration Christening of our organization as “Virchow Biotech” was the result of an inspiration drawn from the German scientist, Dr. Rudolf Ludwig Karl Virchow, the Father of Modern Pathology. Our ideology takes wings from the noted cell theory of Dr Virchow which stands as the "biogenic law" in today’s world. “All living cells arise from pre-existing cells” From inspiration to reality… Inspired by Dr. Virchow, Virchow Laboratories began its journey towards becoming the company that leading pharmaceutical companies look upon to provide state-of-the-art, innovative active pharmaceutical ingredients and formulated products. A ground-breaking commercial process for the development of Sulfamethoxazole in 1977 marked the beginning of our drawn association with our partners. Today we are the largest producer of this drug in the world, serving over 90% of the world wide requirement. The seed sown by group medical veterans, with expertise in the area of modern pharmaceutical manufacturing, has bloomed to span the globe in over 3 decades.

	Values that reflects what we stand for Our Mission: To design, deliver and manufacture innovative products of the highest possible quality; that achieve maximum customer satisfaction. To provide services that support the needs of individuals all over the world. Our Vision: Domain excellence that sets a new benchmark in the healthcare field & hailed as the most admired company by all stakeholders. Our winning culture: Our commitment to quality means being absolutely clear about how we work and what we stand for. Our promise: Strive to improve our business in a way that also improves lives of people around us.

	Global Reach The great thing in the world is not so much where we stand, as in what direction we are moving. Virchow group has achieved a distinct image and identity of an Indian multinational company. Virchow is represented by affiliates and distribution partners in key markets around the world. An extensive integrated network spanning over 13 countries throughout the Americas (including Mexico), Europe (both western and eastern Europe) and Asia (including facilities in China) helps leverage global efficiencies better. We presently have our biopharmaceuticals/formulations registered in more than 20 countries spread over Latin America, CIS, Africa and Asia Pacific regions.

	Virchow Family Today, Virchow group comprises six API and drug intermediate manufacturing units and two biotech units. These include: • Virchow Labs - the world's largest manufacturer of Sulfamethoxazole API • Virchow Biotech - manufacturer of Fermentation and Recombinant Biotech products • Virchow Drugs - manufacturer of Sulfa drugs • Ocimum biosolutions - provider of Drug discovery series • Saraca Labs - world's largest manufacturer of Ranitidine API • Covalent Labs - manufacturer of Cephalosporin APIs • Virchow Chemicals and Petrochemicals - manufacturer of intermediate Note: for more information log on to www.virchows.com

	Milestones of success Unless you try to do something beyond what you have already mastered, you will never grow OUR ACHIEVEMENTS 1981 Dr. Reddy sets up the Flagship Company Virchow Laboratories Ltd. 1992 Established Saraca Laboratories with an aim to manufacture Bulk Drugs & Intermediates. 1995 WHO GMP, EU GMP certification. 1998 Started production of Ranitidine HCL & in a short span of time has become one of the largest manufacturers in the world. 2001 Launched the bio-pharmaceutical company Virchow biotech focusing on wide range of biological & biogenetics by genetic engineering in consortium with a group of biotechnologists based at Vanderbilt University, Nashville, TN, USA. EDQM certification.Became largest producer of Sulfamethoxazole with an output of 400 MT per annum. Services more than 90% of the worldwide Sulfamethoxazole requirement. 2002 Acquired Covalent Laboratories (P) Ltd, a multi-product with GMP certified Cephalosporin API manufacturing facility with a capacity of 240 MT of Cephalosporin API. 2003 US FDA Approval. 2005 First to commercialise in India the bio-generic of the only genetically engineered product for wound healing PDGF to have been approved by USFDA. 2007 First to launch indigenous generic PTH Teriparatide and Interferon & Peg interferon in India. Launched dedicated Advanced Wound Care division to market PDGF, Hemostats, and unique SAP (Sub atmospheric pressure) therapy. 2008 Launched Virchow Healthcare Ltd, focusing on the growing global emerging market needs. Signed MOU with then no.2 Pharma Company in India to market Virchow’s indigenously developed recombinant therapeutic protein for osteoporosis treatment and Interferon, Pegylated Interferon & Ribavirin for Hepatitis management. 2011 Out-licensing agreement with leading Pharma companies to market biotech range. 2012 Launched domestic marketing arm under the banner of flagship company Virchow Laboratories Ltd with cost effective, quality solutions for complete Hepatitis and Osteoporosis management.

	Research & Development Innovation is the vital spark of all human change, improvement and progress • Recognized by Department of Scientific and Industrial Research, Gov. of India as an ‘In- House R&D Unit’. • Ongoing Ph.D program: Registration with Osmania, Nagarjuna and Jawaharlal Nehru Technological universities. Currently several scientists have registered for Ph.D in the areas of Bio-products process development, Fermentation, Molecular Biology, Protein purification, Microbiology, & Cell biology. • Credited with various patents and international publications on undertaken work. Research & Development collaboration: • Centre for Cellular and Molecular Biology, Hyderabad, AP, India • Indian Institute of Chemical Technology, Hyderabad, AP, India • National Institute of Nutrition, Hyderabad, AP, India • University of Michigan, Ann Arbor, MI, USA • Vanderbilt University, Nashville, TN, USA

	Solutions for a better world Act as if what you do makes a difference. It does. A comprehensive range of products that covers various therapy areas: • Gastroenterology • Orthopedics • Endocrinology • Advance Wound Care • Opthalmology • Hematinics • Anti microbials • Hemostats • Neutraceuticals R&D Pipeline in advance stage of development: • Cosmetic surgery • Gastro surgery • Gynaecology • Oncology • Dental • Cardiovascular • HIV • Biosurgery • Wound care